“Host–rabies virus protein–protein interactions as druggable antiviral targets” featured in volume 110 of PNAS. Read here.

“Targeting viral capsid assembly” is featured on front page of Science-Businss eXchange newsletter. Read it here.

“To Stop Rabies, Stop Helping It,” describing Prosetta Antiviral’s novel rabies research, is featured in National Geographic. Read it here.

San Francisco, CA. — Prosetta Antiviral Inc today announced the execution of a strategic alliance with Bristol-Myers Squibb Company (NYSE: BMY) to further discover and develop select drug candidates representing new, novel classes of antiviral drugs. Prosetta currently has a portfolio comprising novel chemical classes of small molecules with robust antiviral activity which target catalytic …

Read about our own Caleb Declouette in a piece about a City College biotechnology program.

Prosetta on NPR as a player in the “Race to Create The Best Antiviral Drugs”.

Read all about the story of Prosetta’s founding and radical approach to antiviral therapy here.

This week, the SF Public Press reviewed Prosetta’s involvement in City College of San Francisco’s Bridges to Biotech program, a certificate program geared toward educating re-entry students in the practices of biotech research. View the full article here.

In early December, Prosetta attended the Cell Symposia: Influenza – Translating basic insights. The poster presented by Prosetta can be viewed here.

During November 1st – 3rd, 1010, Prosetta attended the Sixth Annual Northeast Biodefense Center Conference and presented its latest advances in Dengue virus (DENV) therapeutic discovery. You can view the poster presented by Prosetta  here.